JP2019535788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535788A5 JP2019535788A5 JP2019528512A JP2019528512A JP2019535788A5 JP 2019535788 A5 JP2019535788 A5 JP 2019535788A5 JP 2019528512 A JP2019528512 A JP 2019528512A JP 2019528512 A JP2019528512 A JP 2019528512A JP 2019535788 A5 JP2019535788 A5 JP 2019535788A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutically acceptable
- halo
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 | |
| US62/426,631 | 2016-11-28 | ||
| PCT/US2017/063231 WO2018098412A1 (en) | 2016-11-28 | 2017-11-27 | Gsk-3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535788A JP2019535788A (ja) | 2019-12-12 |
| JP2019535788A5 true JP2019535788A5 (enExample) | 2022-03-01 |
| JP7114591B2 JP7114591B2 (ja) | 2022-08-08 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528512A Active JP7114591B2 (ja) | 2016-11-28 | 2017-11-27 | Ｇｓｋ－３阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (enExample) |
| EP (1) | EP3544613B1 (enExample) |
| JP (1) | JP7114591B2 (enExample) |
| KR (1) | KR102575990B1 (enExample) |
| CN (1) | CN110545817B (enExample) |
| ES (1) | ES2878078T3 (enExample) |
| MA (1) | MA46889A (enExample) |
| WO (1) | WO2018098412A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053258B2 (en) * | 2016-11-28 | 2021-07-06 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as GSK-3 inhibitors |
| CA3123227A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| CA3147272A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| WO2024233900A1 (en) * | 2023-05-10 | 2024-11-14 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| AU2014347027A1 (en) * | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| KR102292433B1 (ko) * | 2013-11-06 | 2021-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 |
| WO2016144797A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| US11053258B2 (en) * | 2016-11-28 | 2021-07-06 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as GSK-3 inhibitors |
-
2017
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en not_active Ceased
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active Active
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507455A5 (enExample) | ||
| JP2015509534A5 (enExample) | ||
| JP2019513745A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| JP2017533968A5 (enExample) | ||
| JP2019510794A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| RU2014145856A (ru) | Азотсодержащее гетероциклическое соединение или его соль | |
| JP2016532673A5 (enExample) | ||
| JP2016512515A5 (enExample) | ||
| JP2014527082A5 (enExample) | ||
| JP2022515293A5 (enExample) | ||
| JP2013525356A5 (enExample) | ||
| JP2019525939A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2015500223A5 (enExample) | ||
| RU2016108038A (ru) | Новые фталазиновые производные и способ их получения | |
| JP2015500257A5 (enExample) | ||
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| JP2017538753A5 (enExample) | ||
| JP7114591B2 (ja) | Ｇｓｋ－３阻害剤 | |
| JP2020529419A5 (enExample) | ||
| JP2013542267A5 (enExample) |